Literature DB >> 8417829

A mechanism for neutrophil-mediated lysis of human neuroblastoma cells.

E Barker1, R A Reisfeld.   

Abstract

Neutrophils mediate the lysis of human neuroblastoma cells coated with human/mouse chimeric anti-GD2 ganglioside antibody ch14.18. This study examined the mechanism(s) by which this occurs. Neutrophil degranulation was found to be a required step for lysis, since release of granular enzymes from neutrophils correlated with the lysis of antibody-coated neuroblastoma cells. In addition, agents which block degranulation specifically inhibited this process. Antibody-dependent lysis of neuroblastoma cells was enhanced by exposing neutrophils to granulocyte-macrophage colony stimulatory factor. An increased release of lytic granular molecules was found to be responsible for this lymphokine-mediated phenomenon. Among the molecules released from neutrophil granules that were shown to be involved in neuroblastoma cell lysis were defensins, M(r) 3000-4000 neutrophil granular proteins which are known to bind and permeabilize tumor cells. In addition, cathepsin-G, a neutrophil granular protease, was demonstrated for the first time to mediate the lysis of human neuroblastoma cells. The enzymatic activity of cathepsin-G was found to be required for the lysis of these tumor cells, since phenylmethylsulfonyl fluoride blocks the lytic ability of this protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417829

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects.

Authors:  Amy A Baxter; Fung T Lay; Ivan K H Poon; Marc Kvansakul; Mark D Hulett
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

2.  Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Authors:  Suzanne Shusterman; Wendy B London; Stephen D Gillies; Jacquelyn A Hank; Stephan D Voss; Robert C Seeger; C Patrick Reynolds; Jennifer Kimball; Mark R Albertini; Barrett Wagner; Jacek Gan; Jens Eickhoff; Kenneth B DeSantes; Susan L Cohn; Toby Hecht; Brian Gadbaw; Ralph A Reisfeld; John M Maris; Paul M Sondel
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

3.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

4.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

5.  Dinutuximab and Panobinostat.

Authors:  Ashley Chasick; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2015-10-14

6.  Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.

Authors:  Irene Y Cheung; Katharine Hsu; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

Review 7.  Immunology and immunotherapy of neuroblastoma.

Authors:  Robert C Seeger
Journal:  Semin Cancer Biol       Date:  2011-09-28       Impact factor: 15.707

Review 8.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

Review 9.  Monoclonal antibody-based therapy for neuroblastoma.

Authors:  N K Cheung
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

Review 10.  Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.

Authors:  Jacob L Goldberg; Paul M Sondel
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.